PolyBio Research Foundation
@polybiorf.bsky.social
501(c)3 transforming how #LongCovid, #ME/CFS & Lyme+ are studied, diagnosed, and treated. Leading the #LongCovid Research Consortium.
Pinned
1/ Introducing PolyBio’s new interactive website module, where you can learn about our #LongCovid Research Consortium projects, technologies, and findings across international institutions:
polybio.org/consortium-p...
polybio.org/consortium-p...
Featured in Bloomberg this week: UCSF’s PolyBio-supported LIINC team and their recent preprint suggesting SARS-CoV-2 viral and protein persistence in the gastrointestinal tracts of a portion of Long COVID patients. 1/
August 14, 2026 at 2:36 PM
Featured in Bloomberg this week: UCSF’s PolyBio-supported LIINC team and their recent preprint suggesting SARS-CoV-2 viral and protein persistence in the gastrointestinal tracts of a portion of Long COVID patients. 1/
PolyBio is supporting research that investigates the bone marrow as a potential long-term SARS-CoV-2 reservoir site. Bone marrow-derived cells, including megakaryocytes and the platelets they produce, have previously been shown to contain SCV2 double-stranded RNA in Long COVID patients’ samples— 1/
August 10, 2026 at 4:44 PM
PolyBio is supporting research that investigates the bone marrow as a potential long-term SARS-CoV-2 reservoir site. Bone marrow-derived cells, including megakaryocytes and the platelets they produce, have previously been shown to contain SCV2 double-stranded RNA in Long COVID patients’ samples— 1/
Dr. Amy Proal in collaboration with the Cohen Center for Recovery from Complex Chronic Illness this week: “A big goal of ours is that [Long COVID] diagnostics are available to be ordered in insurance care for the most number of patients…
July 17, 2026 at 8:10 PM
Dr. Amy Proal in collaboration with the Cohen Center for Recovery from Complex Chronic Illness this week: “A big goal of ours is that [Long COVID] diagnostics are available to be ordered in insurance care for the most number of patients…
“What we’re finding across the genome are specific variants that are very much enriched, and have highly likely loss-of-function in these patients with [severe] Long COVID,” said Dr. Petter Brodin on his team’s PolyBio-supported genome study of Long COVID patients.
June 16, 2026 at 1:59 AM
“What we’re finding across the genome are specific variants that are very much enriched, and have highly likely loss-of-function in these patients with [severe] Long COVID,” said Dr. Petter Brodin on his team’s PolyBio-supported genome study of Long COVID patients.
Written summaries of PolyBio’s Spring symposium presentations are available now! Check out shortened, simplified summaries, or full technical explanations of your favourite research projects.
2026-spring-symposium-polybio.netlify.app
#Longcovidresearch #mecfsresearch #chroniclymedisease
2026-spring-symposium-polybio.netlify.app
#Longcovidresearch #mecfsresearch #chroniclymedisease
June 1, 2026 at 7:55 PM
Written summaries of PolyBio’s Spring symposium presentations are available now! Check out shortened, simplified summaries, or full technical explanations of your favourite research projects.
2026-spring-symposium-polybio.netlify.app
#Longcovidresearch #mecfsresearch #chroniclymedisease
2026-spring-symposium-polybio.netlify.app
#Longcovidresearch #mecfsresearch #chroniclymedisease
Breaking: Funding from Vitalik Buterin’s Balvi Fund Expands Long COVID Low-Dose Rapamycin Clinical Trial with a New Open-Label Phase
1/
1/
May 29, 2026 at 7:19 PM
Breaking: Funding from Vitalik Buterin’s Balvi Fund Expands Long COVID Low-Dose Rapamycin Clinical Trial with a New Open-Label Phase
1/
1/
Breaking: PolyBio-Supported Study Identifies Association between HHV-6 Reactivation & Long COVID Symptom Severity
The work adds to growing evidence that chronic viral reactivation may contribute to the biological mechanisms underlying Long COVID.
Read more: polybio.org/polybio-supp...
The work adds to growing evidence that chronic viral reactivation may contribute to the biological mechanisms underlying Long COVID.
Read more: polybio.org/polybio-supp...
May 23, 2026 at 5:58 PM
Breaking: PolyBio-Supported Study Identifies Association between HHV-6 Reactivation & Long COVID Symptom Severity
The work adds to growing evidence that chronic viral reactivation may contribute to the biological mechanisms underlying Long COVID.
Read more: polybio.org/polybio-supp...
The work adds to growing evidence that chronic viral reactivation may contribute to the biological mechanisms underlying Long COVID.
Read more: polybio.org/polybio-supp...
Excited for PolyBio’s upcoming Spring symposium on Friday, May 22 from 11 AM to 5 PM ET? Here’s the full program of presenters you’ll hear from!
2026 Spring Symposium - PolyBio Research Foundation
polybio.org
May 9, 2026 at 9:00 PM
Excited for PolyBio’s upcoming Spring symposium on Friday, May 22 from 11 AM to 5 PM ET? Here’s the full program of presenters you’ll hear from!
Catch Dr. Michael Peluso, part of the PolyBio-supported Long COVID tissue bank & LIINC collaborative, in Men’s Health this week!
Read the full article here: www.menshealth.com/health/a7113...
#longcovidtreatment #longcovidresearch #menshealth
Read the full article here: www.menshealth.com/health/a7113...
#longcovidtreatment #longcovidresearch #menshealth
May 8, 2026 at 7:49 PM
Catch Dr. Michael Peluso, part of the PolyBio-supported Long COVID tissue bank & LIINC collaborative, in Men’s Health this week!
Read the full article here: www.menshealth.com/health/a7113...
#longcovidtreatment #longcovidresearch #menshealth
Read the full article here: www.menshealth.com/health/a7113...
#longcovidtreatment #longcovidresearch #menshealth
Park-Pagliuca Fund Donates $10 Million to PolyBio Long COVID Cure Initiative
The funding will fast-track Long COVID diagnostics and treatments 🧵
www.prnewswire.com/news-release...
The funding will fast-track Long COVID diagnostics and treatments 🧵
www.prnewswire.com/news-release...
April 27, 2026 at 2:06 PM
Park-Pagliuca Fund Donates $10 Million to PolyBio Long COVID Cure Initiative
The funding will fast-track Long COVID diagnostics and treatments 🧵
www.prnewswire.com/news-release...
The funding will fast-track Long COVID diagnostics and treatments 🧵
www.prnewswire.com/news-release...
Save the date! PolyBio’s Spring symposium will take place on Friday, May 22 11-5 PM ET. It will feature project updates on Long COVID, ME/CFS, Alzheimer’s & chronic tick-borne disease research that is advancing how we diagnose & treat IACIs. Sign up now:
us02web.zoom.us/webinar/regi...
us02web.zoom.us/webinar/regi...
April 21, 2026 at 3:44 PM
Save the date! PolyBio’s Spring symposium will take place on Friday, May 22 11-5 PM ET. It will feature project updates on Long COVID, ME/CFS, Alzheimer’s & chronic tick-borne disease research that is advancing how we diagnose & treat IACIs. Sign up now:
us02web.zoom.us/webinar/regi...
us02web.zoom.us/webinar/regi...
BREAKING: VIPER Diagnostics Program Launches as First Phase of PolyBio Long COVID Cure Initiative
Program will validate diagnostic tests for SARS-CoV-2 persistence and other drivers of Long COVID, providing a path to targeted treatments.
Program will validate diagnostic tests for SARS-CoV-2 persistence and other drivers of Long COVID, providing a path to targeted treatments.
March 24, 2026 at 3:29 PM
BREAKING: VIPER Diagnostics Program Launches as First Phase of PolyBio Long COVID Cure Initiative
Program will validate diagnostic tests for SARS-CoV-2 persistence and other drivers of Long COVID, providing a path to targeted treatments.
Program will validate diagnostic tests for SARS-CoV-2 persistence and other drivers of Long COVID, providing a path to targeted treatments.
PolyBio Research Foundation is keeping you in-the-know with our newly launched newsletter! Sign up for our mailing list to get direct project updates to your inbox & meet the team that drives our research forward.
polybio.org/newsletter/
polybio.org/newsletter/
March 23, 2026 at 2:05 PM
PolyBio Research Foundation is keeping you in-the-know with our newly launched newsletter! Sign up for our mailing list to get direct project updates to your inbox & meet the team that drives our research forward.
polybio.org/newsletter/
polybio.org/newsletter/
Interested in low-dose Rapamycin for Long Covid? The Cohen Center for Recovery from Complex Chronic Illness is actively recruiting for a RCT of the mTOR inhibitor Sirolimus (Rapamycin). The trial aims to evaluate if changes to the immune response as a result of the drug improve Long Covid symptoms.
February 25, 2026 at 9:38 PM
Interested in low-dose Rapamycin for Long Covid? The Cohen Center for Recovery from Complex Chronic Illness is actively recruiting for a RCT of the mTOR inhibitor Sirolimus (Rapamycin). The trial aims to evaluate if changes to the immune response as a result of the drug improve Long Covid symptoms.
1/ Long Covid, ME/CFS and Post-Treatment Lyme patients living in NYC: Mount Sinai’s CoRE clinic is actively recruiting for a clinical trial of Lumbrokinase. This enzyme breaks down fibrin, a coagulation factor linked to chronic symptoms,
February 13, 2026 at 7:06 PM
1/ Long Covid, ME/CFS and Post-Treatment Lyme patients living in NYC: Mount Sinai’s CoRE clinic is actively recruiting for a clinical trial of Lumbrokinase. This enzyme breaks down fibrin, a coagulation factor linked to chronic symptoms,
PolyBio scientific advisory board member Dr. William Eimer led the recent discovery of beta-amyloid & tau proteins’ antimicrobial activity targeting Herpes Simplex Virus 1 in the brain. (1/2)
February 9, 2026 at 10:30 PM
PolyBio scientific advisory board member Dr. William Eimer led the recent discovery of beta-amyloid & tau proteins’ antimicrobial activity targeting Herpes Simplex Virus 1 in the brain. (1/2)
PolyBio CEO Dr. Amy Proal & PolyBio-supported researchers Timothy Henrich MD & Steven Deeks MD recently presented data on Long Covid tissue findings at the inaugural USA-Saudi Biotech Alliance summit.
polybio.org/polybio-scie...
polybio.org/polybio-scie...
January 31, 2026 at 8:46 PM
PolyBio CEO Dr. Amy Proal & PolyBio-supported researchers Timothy Henrich MD & Steven Deeks MD recently presented data on Long Covid tissue findings at the inaugural USA-Saudi Biotech Alliance summit.
polybio.org/polybio-scie...
polybio.org/polybio-scie...
Want first access to antiviral therapies for Long Covid? We’re looking for participants for a clinical trial of Truvada & Maraviroc. The trial is using cutting-edge biological markers including deep immune profiling & EndoPAT to determine efficacy of these medications in LC.
January 27, 2026 at 6:29 PM
Want first access to antiviral therapies for Long Covid? We’re looking for participants for a clinical trial of Truvada & Maraviroc. The trial is using cutting-edge biological markers including deep immune profiling & EndoPAT to determine efficacy of these medications in LC.
BREAKING: PolyBio Core Team Collaborating with Invivyd for Trial of the mAb VYD2311, Launching mid-2026
This week, Invivyd announced the upcoming launch of a new randomized, double-blind clinical trial of the monoclonal antibody WYD2311 in people with Long Covid and COVID vaccine injury.
This week, Invivyd announced the upcoming launch of a new randomized, double-blind clinical trial of the monoclonal antibody WYD2311 in people with Long Covid and COVID vaccine injury.
investors.invivyd.com
January 21, 2026 at 5:40 PM
BREAKING: PolyBio Core Team Collaborating with Invivyd for Trial of the mAb VYD2311, Launching mid-2026
This week, Invivyd announced the upcoming launch of a new randomized, double-blind clinical trial of the monoclonal antibody WYD2311 in people with Long Covid and COVID vaccine injury.
This week, Invivyd announced the upcoming launch of a new randomized, double-blind clinical trial of the monoclonal antibody WYD2311 in people with Long Covid and COVID vaccine injury.
“We found evidence of SARS-CoV-2 infected cells both in the gut and female reproductive tract… more than 4 years after the initial infection,” said Dr. Marta Mirabent, who is part of the Roan lab team investigating SCV2 persistence in these sites as driver of Long Covid.
January 12, 2026 at 10:58 PM
“We found evidence of SARS-CoV-2 infected cells both in the gut and female reproductive tract… more than 4 years after the initial infection,” said Dr. Marta Mirabent, who is part of the Roan lab team investigating SCV2 persistence in these sites as driver of Long Covid.
Reflecting on 2025, PolyBio helped lead the fight against Long Covid. We supported 6 clinical trials, started the Long Covid cure initiative, and began charting the route towards validated biomarkers. We’re looking forward to continuing to drive innovation for IACIs in 2026.
January 2, 2026 at 6:26 PM
Reflecting on 2025, PolyBio helped lead the fight against Long Covid. We supported 6 clinical trials, started the Long Covid cure initiative, and began charting the route towards validated biomarkers. We’re looking forward to continuing to drive innovation for IACIs in 2026.
To wrap-up our countdown to 2026, we’re highlighting PolyBio’s key contribution to the UCSF LIINC Anktiva trial for Long Covid. The funding will allow advanced testing of patient samples to track changes in SARS-CoV-2 persistence over time.
January 1, 2026 at 12:26 AM
To wrap-up our countdown to 2026, we’re highlighting PolyBio’s key contribution to the UCSF LIINC Anktiva trial for Long Covid. The funding will allow advanced testing of patient samples to track changes in SARS-CoV-2 persistence over time.
No.11 on our 2026 countdown: PolyBio began a collaboration with 60 Degrees Pharma on a clinical trial of Tafenoquine for Chronic Babesiosis. The trial is a crucial step forward in finding effective therapies for the disease, which currently has no FDA-approved treatments.
#polybio2026countdown
#polybio2026countdown
December 31, 2025 at 8:27 PM
No.11 on our 2026 countdown: PolyBio began a collaboration with 60 Degrees Pharma on a clinical trial of Tafenoquine for Chronic Babesiosis. The trial is a crucial step forward in finding effective therapies for the disease, which currently has no FDA-approved treatments.
#polybio2026countdown
#polybio2026countdown
PolyBio’s influential 2025 moments no.10: our contribution to developing advanced diagnostics for Babesiosis. The new methods will allow the research team to assess the prevalence of different Babesia species in over 1400 patients with a spectrum of cardiac, rheumatological & neurological disorders.
December 30, 2025 at 10:51 PM
PolyBio’s influential 2025 moments no.10: our contribution to developing advanced diagnostics for Babesiosis. The new methods will allow the research team to assess the prevalence of different Babesia species in over 1400 patients with a spectrum of cardiac, rheumatological & neurological disorders.
No.9 on PolyBio’s End-of-Year countdown: the Banbury meeting on accessible diagnostics of pathogen tissue persistence. The meeting brought together leading scientists to accelerate progress toward reliable diagnostics for infection-associated chronic diseases, including Long COVID.
December 29, 2025 at 10:13 PM
No.9 on PolyBio’s End-of-Year countdown: the Banbury meeting on accessible diagnostics of pathogen tissue persistence. The meeting brought together leading scientists to accelerate progress toward reliable diagnostics for infection-associated chronic diseases, including Long COVID.